SYNENDOS THERAPEUTICS
Synendos Therapeutics develops a class of small molecules for the treatment of anxiety and stress-related disorders. The company also develops breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of the natural functioning of the brain. The inhibitors act with a new mechanism of action that enables restoration of the natural function of the brain by rebalancing altered neurotransmission in different areas of the bran. There is a high demand for new pharmacological treatments in this area especially for certain diseases such as post-traumatic stress disorder (PTSD) which has a high unmet medical need.
SYNENDOS THERAPEUTICS
Industry:
Health Care Medical Therapeutics
Founded:
2019-04-01
Address:
Allschwil, Basel-Landschaft, Switzerland
Country:
Switzerland
Website Url:
http://www.synendos.com
Total Employee:
11+
Status:
Active
Total Funding:
44.15 M CHF
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Content Delivery Network Wix Lorem Ipsum Wix Media Wix Bookings Getty Images
Similar Organizations
Aardvark Therapeutics
Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
C4 Therapeutics
C4 Therapeutics develops novel early stage therapies that eliminate disease-causing proteins.
Interline Therapeutics
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Viking Therapeutics
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.
Current Advisors List
Current Employees Featured
Founder
Investors List
Ysios Capital
Ysios Capital investment in Series A - Synendos Therapeutics
Lichtsteiner Foundation
Lichtsteiner Foundation investment in Series A - Synendos Therapeutics
Zürcher Kantonal Bank
Zürcher Kantonal Bank investment in Series A - Synendos Therapeutics
HTGF | High-Tech Gruenderfonds
HTGF | High-Tech Gruenderfonds investment in Series A - Synendos Therapeutics
Kurma Partners
Kurma Partners investment in Series A - Synendos Therapeutics
Essential Investment Partners
Essential Investment Partners investment in Series A - Synendos Therapeutics
Bernina BioInvest
Bernina BioInvest investment in Series A - Synendos Therapeutics
Schroder Adveq
Schroder Adveq investment in Series A - Synendos Therapeutics
Sunstone Life Science Ventures
Sunstone Life Science Ventures investment in Series A - Synendos Therapeutics
Venture Kick
Venture Kick investment in Pre Seed Round - Synendos Therapeutics
Newest Events participated
Official Site Inspections
http://www.synendos.com Semrush global rank: 11.64 M Semrush visits lastest month: 154
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.171
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Synendos Therapeutics"
Team - Synendos Therapeutics
The team of Synendos Therapeutics AG. Andrea holds a PhD in Pharmacology and has over 15+ years of professional experience.. Following his initial post-doctoral study, Andrea served as a scientific advisor in the corporate …See details»
Synendos Therapeutics - Crunchbase Company Profile & Funding
Synendos Therapeutics develops a class of small molecules for the treatment of anxiety and stress-related disorders. The company also develops breakthrough safe and effective …See details»
Org Chart Synendos Therapeutics - The Official Board
Organizational Chart of Synendos Therapeutics. Synendos Therapeutics www.synendos.com. has 11 executives +41 613 311 212; Add an executive. Synendos Therapeutics News . …See details»
October 2024 // Funding & Investment - synendos.com
Synendos AG is excited to announce that it has been awarded a grant under the highly competitive Start-Up Innovation Project (SIP) scheme of Innosuisse which aims to support …See details»
Synendos Therapeutics Company Profile 2024: Valuation, Funding ...
Synendos Therapeutics has 9 total employees. What industry is Synendos Therapeutics in? Synendos Therapeutics’s primary industry is Drug Discovery. Is Synendos Therapeutics a …See details»
Synendos Therapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money ... obfuscated. Venture Kick: Oct 15, 2019: Pre Seed …See details»
Synendos Therapeutics AG – Swiss Biotech
Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a …See details»
Synendos Therapeutics - VentureRadar
" Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a …See details»
Synendos Therapeutics - Overview, News & Similar companies
Jul 18, 2023 Who is Synendos Therapeutics. Synendos Therapeutics is a biopharmaceutical company developing a new class of small molecules aimed at restoring the natural functioning …See details»
Synendos Therapeutics AG - LinkedIn
Synendos Therapeutics AG | 2,291 followers on LinkedIn. Breakthrough safe and effective therapies for neuropsychiatric disorders | Synendos Therapeutics AG is a biopharmaceutical …See details»
Synendos Therapeutics - Crunchbase
Synendos Therapeutics develops a class of small molecules for the treatment of anxiety and stress-related disorders. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. …See details»
January 2024 // Company & Communication - Synendostherapeutics
Synendos granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510.Synendos transitions to a clinical-stage biotech company developing …See details»
Synendos Therapeutics - Contacts, Employees, Board Members
Organization. Synendos Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... Advisor Profiles 3. Contacts 4. About. Synendos Therapeutics …See details»
News | Synendos therapeutics
The main news about Synendos therapeutics. top of page. FOUNDING TEAM. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis …See details»
Synendos Therapeutics - Updates, News, Events, Signals & Triggers
Synendos Therapeutics develops a class of small molecules for the treatment of anxiety and stress-related disorders. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. …See details»
Synendos Therapeutics Expands Series A to CHF 24 million with …
BASEL, Switzerland, April 20, 2021 /PRNewswire/ -- Synendos Therapeutics (Synendos), a biopharmaceutical company focused on restoring the natural functioning of the …See details»
FOUNDING TEAM - synendos.com
Synendos Therapeutics is thrilled to announce the formation of the Scientific Advisory Board. September 2019 // Company. Synendos selected for the Innousuisse start-up core coaching …See details»
Synendos Therapeutics - Tech Stack, Apps, Patents & Trademarks
These include Organization Schema, U.S. Server Location, and Person Schema. Website Tech Stack by BuiltWith. Edit Website Tech Stack by BuiltWith Section. ... Synendos Therapeutics is …See details»
Approach - Synendos therapeutics
Synendos has conducted market research with over 40 KOLs across the major markets, exploring the unmet needs in PTSD and the attractiveness of the profile associated with a novel SERI …See details»